2023-03-06 10:53:39 ET
- Amarin Corp. ( NASDAQ: AMRN ), maker of the prescription fish oil pill Vascepa, has unviled in vitro data it says supports the potential mechanistic effects of omega-3 fatty acid eicosapentaenoic acid (EPA) in reducing cardiovascular event.
- Vascepa's active ingredient, icosapent ethyl, is a novel formulation of EPA.
- Analyses indicated that EPA is highly effective in reducing lipoprotein oxidation, one of the conditions that leads to atherosclerosis.
- Amarin ( AMRN ) noted that this finding may explain why the Vascepa REDUCE-IT trial showed CV risk reduction benefits.
- The data was presented Monday at the World Congress of Cardiology.
- Read why Seeking Alpha contributor Allen Cooke issued a buy rating for Amarin ( AMRN ).
For further details see:
Amarin touts in vitro data on omega-3 fatty acid EPA in reducing cardiovascular events